Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren… - European heart …, 2020 - academic.oup.com
Abstract Aims The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS)
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren, P Libby - 2020 - pubmed.ncbi.nlm.nih.gov
Aims The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS)
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren, P Libby - European Heart Journal, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Aims</jats: title>< jats: p> The
Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) established that …
Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) established that …
[PDF][PDF] Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren… - European Heart …, 2020 - academic.oup.com
Abstract Aims The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS)
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren… - European Heart …, 2020 - europepmc.org
Aims The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS)
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren… - European Heart …, 2020 - search.ebscohost.com
Abstract Aims The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS)
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …